文献速递神经肿瘤

谷氨酸调节与抗PD-1免疫治疗在胶质母细胞瘤中的协同作用

Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma.
PubMed 文献 · J Neurosurg · 2021-08-13

该研究在GL261胶质瘤小鼠模型中探讨谷氨酸调节剂BHV-4157与抗PD-1免疫治疗的协同作用。BHV-4157单药改善生存并降低肿瘤微环境谷氨酸浓度,增加CD4+ T细胞、减少Foxp3+ T细胞,且其疗效依赖CD4+和CD8+ T细胞。研究表明两者存在协同作用,为胶质母细胞瘤联合治疗提供依据。

要点

  • BHV-4157单药较对照组显著改善GL261荷瘤小鼠生存(p < 0.0001)。
  • BHV-4157给药后肿瘤微环境谷氨酸浓度显著下降。
  • BHV-4157疗效依赖CD4+和CD8+ T细胞,耗竭后生存获益消失(p < 0.05)。

核心结论

  • 抗PD-1免疫治疗与谷氨酸调节在胶质母细胞瘤小鼠模型中显示协同作用。
  • BHV-4157通过依赖CD4+和CD8+ T细胞的机制发挥疗效。
  • 肿瘤微环境中过量谷氨酸可能在胶质母细胞瘤免疫抑制中起作用。

研究设计与样本

  • C57BL/6J小鼠颅内植入荧光素酶标记的GL261胶质瘤细胞。
  • 小鼠随机分为对照、抗PD-1、BHV-4157及抗PD-1联合BHV-4157治疗组,评估中位总生存期。
  • 在肿瘤部位进行在体微透析,并用免疫荧光和流式细胞术表征瘤内免疫细胞群。

主要发现

  • BHV-4157治疗组较对照组生存改善(p < 0.0001)。
  • 微透析显示BHV-4157给药后肿瘤微环境谷氨酸浓度显著下降。
  • 免疫荧光和流式细胞术显示BHV-4157治疗小鼠CD4+ T细胞增加、Foxp3+ T细胞减少。
  • 在BHV-4157给药前耗竭CD4+或CD8+ T细胞的小鼠未观察到生存获益(p < 0.05)。

临床怎么用

  • 提示谷氨酸调节联合抗PD-1可能成为胶质母细胞瘤的联合治疗策略。
  • BHV-4157的疗效依赖于CD4+和CD8+ T细胞,支持免疫机制参与。
  • 目前仅为小鼠临床前证据,尚不能直接指导临床用药。

局限性

  • 研究仅使用GL261小鼠胶质瘤模型,结果外推到人类胶质母细胞瘤需谨慎。
  • 原文未报告BHV-4157的剂量、给药方案及联合治疗组的具体生存数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Immune checkpoint inhibitors such as anti-programmed cell death protein 1 (anti-PD-1) have shown promise for the treatment of cancers such as melanoma, but results for glioblastoma (GBM) have been disappointing thus far. It has been suggested that GBM has multiple mechanisms of immunosuppression, indicating a need for combinatorial treatment strategies. It is well understood that GBM increases glutamate in the tumor microenvironment (TME); however, the significance of this is not well understood. The authors posit that glutamate upregulation in the GBM TME is immunosuppressive. The authors utilized a novel glutamate modulator, BHV-4157, to determine synergy between glutamate modulation and the well-established anti-PD-1 immunotherapy for GBM. METHODS: C57BL/6J mice were intracranially implanted with luciferase-tagged GL261 glioma cells. Mice were randomly assigned to the control, anti-PD-1, BHV-4157, or combination anti-PD-1 plus BHV-4157 treatment arms, and median overall survival was assessed. In vivo microdialysis was performed at the tumor site with administration of BHV-4157. Intratumoral immune cell populations were characterized with immunofluorescence and flow cytometry. RESULTS: The BHV-4157 treatment arm demonstrated improved survival compared with the control arm (p < 0.0001). Microdialysis demonstrated that glutamate concentration in TME significantly decreased after BHV-4157 administration. Immunofluorescence and flow cytometry demonstrated increased CD4+ T cells and decreased Foxp3+ T cells in mice that received BHV-4157 treatment. No survival benefit was observed when CD4+ or CD8+ T cells were depleted in mice prior to BHV-4157 administration (p < 0.05). CONCLUSIONS: In this study, the authors showed synergy between anti-PD-1 immunotherapy and glutamate modulation. The authors provide a possible mechanism for this synergistic benefit by showing that BHV-4157 relies on CD4+ and CD8+ T cells. This study sheds light on the role of excess glutamate in GBM and provides a basis for further exploring combinatorial approaches for the treatment of this disease.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Medikonda R, Choi J, Pant A, et al. Synergy between glutamate modulation and anti-programmed cell death protein 1 immunotherapy for glioblastoma. J Neurosurg. 2021. PMID: 34388730. doi:10.3171/2021.1.JNS202482

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。